Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study

Silini, Enrico Maria; Bottelli, R.; Asti, M.; Bruno, S.; Candusso, Maria Elena; Brambilla, Silvia; Bono, Fulvia; Iamoni, Gianmaria; Tinelli, Carmine; Mondelli, Mario U.; Ideo, G.

doi:10.1097/00042737-199611000-00023

Cited by 28 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 It is of interest, howhave clearly shown the emergence of ''new'' genotypes in ever, that, in Japan 40 and Southern Italy, 41 where HCV type younger European patients. 26,27 However, in this and in a 1b infection is predominant, the incidence of HCC in antilarger case-control study of 385 anti-HCV-positive cirrhotic HCV-positive cirrhotic patients is higher than in our geopatients with or without HCC, 24 we were not able to detect graphic area. 3,6 Moreover, it would also be important to prodifferences in patients' ages according to HCV type, sugspectively analyze patients presenting with a whole spectrum gesting that a cohort effect was highly unlikely in this setting.…”

Section: Discussionmentioning

confidence: 53%

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study

Bruno¹,

Silini²,

Crosignani³

et al. 1997

Hepatology

Self Cite

325

193

View full text Add to dashboard Cite

approximately 3%. 3,4 Early detection of HCC in cirrhotic pa-A prospective study was performed to establish tients can usually be achieved by screening with noninvasive whether infection with specific hepatitis C virus (HCV) techniques, such as ultrasound (US) scan and serum a-fetogenotypes was associated with an increased risk of protein (AFP) concentration. 5,6 development of hepatocellular carcinoma (HCC) in cirOver the years, several lines of experimental evidence indirhosis. A cohort of 163 consecutive hepatitis C virus anticated that male sex, age, and alcohol consumption 4,7,8 were body (anti-HCV)-positive cirrhotic patients was proclosely associated with the development of HCC in cirrhotic spectively evaluated for the development of HCC at patients. The identification of additional variables associated 6-month intervals by ultrasound (US) scan and awith an increased risk of developing HCC would be particufetoprotein (AFP) concentration. HCV genotypes were larly important to optimize preventive medical programs in determined according to Okamoto. Risk factors associthis setting. Recent studies suggested a possible role for HCV ated with cancer development were analyzed by univarigenotype in chronic liver disease outcome and, specifically, ate and multivariate statistics. At enrollment, 101 pa-HCV type 1 was more frequently found in advanced liver tients (62%) were infected with type 1b, 48 (29.5%) were disease, such as cirrhosis and HCC, 9-11 and was associated infected with type 2a/c, 2 (1.2%) were infected with type with a more rapid deterioration of liver histology in chronic 3a, 1 (0.6%) was infected with type 1a, 3 (1.8%) had a hepatitis. 12 We have studied the distribution of HCV genomixed-type infection, and, in 8 patients (4.9%), genotype types in a cohort of patients with cirrhosis prospectively folcould not be assigned. After a 5-to 7-year follow-up (melowed for early detection of HCC, and we performed multivardian, 68 months), HCC developed in 22 of the patients, iate analysis to evaluate the independent risk for tumor 19 infected with type 1b and 3 with type 2a/c (P õ .005).development associated with specific HCV types and with Moreover, HCC developed more frequently in males (P other variables, including interferon treatment, which has õ .01), patients with excessive alcohol intake (P õ .01), been recently reported to reduce the cancer risk in HCVthose over 60 years of age (P õ .02), and in patients who induced cirrhosis. ated with the development of cirrhosis. 1 HCV infection alone was also calculated. Aliquots of sera collected at entry were stored accounts for over 25% of all cases of cirrhosis in Italy, 2 a at 030ЊC for further serological and molecular analysis. When hepacondition that is associated with an increased risk of hepato-titis C virus antibody (anti-HCV) serology became available, sera cellular carcinoma (HCC), with a yearly incidence rate of from 472 of 501 patients were tested by second-generation enzyme immunoassay (Ortho Diagnostic Systems, Raritan, NJ), and 240 sub...

show abstract

Section: Discussionmentioning

confidence: 53%

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study

Bruno¹,

Silini²,

Crosignani³

et al. 1997

Hepatology

Self Cite

325

193

View full text Add to dashboard Cite

show abstract

“…Evidence is strongest in HCV, in which genotype 1b appears to be associated with an increased risk of HCC. [100][101][102] There is little evidence surrounding the relationship between viral genotype and carcinogenesis in HBV. A study from Taiwan suggests that genotype C may be more carcinogenic; however, this genotype is uncommon in Western populations.…”

Section: Aetiologymentioning

confidence: 99%

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Coon¹,

Rogers²,

Hewson³

et al. 2007

Health Technol Assess

151

108

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: K Stein received an unrestricted grant from Schering Plough (UK) to carry out work on the cost-effectiveness of combination therapy for hepatitis C in 2000. KS is also a member of the editorial board for Health Technology Assessment, but he was not involved in the editorial process for this report. M Cramp sits on hepatitis C advisory boards for Schering Plough, Gilead and Roche. He has received unrestricted educational grants from Roche and Schering Plough to support research and service development. He has been awarded an NHS R&D grant looking at injecting drug users who do not have hepatitis C virus infection. J Thompson Coon received a grant from the Hepatitis C Trust to conduct a systematic review of complementary and alternative therapies for the treatment of chronic hepatitis C. HTA Published September 2007This report should be referenced as follows: NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, man...

show abstract

“…In several early studies, HCV genotype 1b was found to be associated with a more severe liver disease, including a higher frequency of cirrhosis and hepatocellular carcinoma. 41 However, many of these studies did not control for important confounding factors, such as age, source, and duration of infection. Genotype 1b is more common among older than younger patients and has been commonly linked to spread by blood transfusion.…”

Section: Factors Associated With Fibrosis Progressionmentioning

confidence: 99%

Fibrosis and disease progression in hepatitis C

2002

View full text Add to dashboard Cite

The progression of fibrosis in chronic hepatitis C determines the ultimate prognosis and thus the need and urgency of therapy. Fibrogenesis is a complex dynamic process, which is mediated by necroinflammation and activation of stellate cells. The liver biopsy remains the gold standard to assess fibrosis. Scoring systems allow a semiquantitative assessment and are useful for cross-sectional and cohort studies and in treatment trials. The rate at which fibrosis progresses varies markedly between patients. The major factors known to be associated with fibrosis progression are older age at infection, male gender, and excessive alcohol consumption. Viral load and genotype do not seem to influence significantly the progression rate. Progression of fibrosis is more rapid in immunocompromised patients. Hepatic steatosis, obesity, and diabetes may also contribute to more rapid progression of fibrosis. There are no tests that reliably predict the rate of progression of fibrosis in an individual patient. High serum alanine aminotransferase (ALT) levels are associated with a higher risk of fibrosis progression, and worsening of fibrosis is uncommon in patients with persistently normal serum aminotransferase levels. Serum markers for fibrosis are not reliable and need to be improved and validated. Liver biopsy provides the most accurate information on the stage of fibrosis and grade of necroinflammation, both of which have prognostic significance. Repeating the liver biopsy, 3 to 5 years after an initial biopsy is the most accurate means of assessing the progression of fibrosis. (HEPATOLOGY 2002;36:S47-S56.)

show abstract

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study

Cited by 28 publications

References 0 publications

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study

Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis

Fibrosis and disease progression in hepatitis C

Contact Info

Product

Resources

About